Is Medico Remedies overvalued or undervalued?

Jun 29 2025 08:02 AM IST
share
Share Via
As of June 27, 2025, Medico Remedies is fairly valued with a PE ratio of 32.96, an EV to EBITDA of 22.96, and a ROE of 16.15%, positioning it competitively against peers like Sun Pharma and Divi's Lab, despite a year-to-date stock decline of 26.38%.
As of 27 June 2025, the valuation grade for Medico Remedies has moved from expensive to fair. The company is currently fairly valued based on its financial metrics. Key ratios include a PE ratio of 32.96, an EV to EBITDA of 22.96, and a ROE of 16.15%.

In comparison to its peers, Medico Remedies stands at a fair valuation with a PE ratio lower than Sun Pharma's 35.42 and Divi's Lab's significantly high 80.92, while being more favorable than Cipla's attractive PE of 23.02. Despite recent stock performance showing a decline of 26.38% year-to-date against a 7.58% increase in the Sensex, the overall valuation suggests that Medico Remedies is positioned reasonably within its industry.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News